{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kadosh BS"],"funding":["NCATS NIH HHS","NHLBI NIH HHS"],"pagination":["2045-2053"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7446967"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(9)"],"pubmed_abstract":["The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19."],"journal":["Arteriosclerosis, thrombosis, and vascular biology"],"pubmed_title":["COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease."],"pmcid":["PMC7446967"],"funding_grant_id":["R01 HL146206","P01 HL131481","P01 HL146367","R35 HL135799","UL1 TR000038","UL1 TR001445","R01 HL132516","K23 HL125991"],"pubmed_authors":["Kadosh BS","Pillinger M","Katz SD","Moore KJ","Ramasamy R","Shah B","Hochman J","Garshick MS","Gaztanaga J","Newman JD","Reynolds HR","Fishman GI"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease.","description":"The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-04-04T10:00:18.676Z","creation":"2020-08-31T07:04:38Z"},"accession":"S-EPMC7446967","cross_references":{"pubmed":["32687400"],"doi":["10.1161/ATVBAHA.120.314513"]}}